Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): actions at serotonin receptors may enhance downstream release of four pro-cognitive neurotransmitters

No abstract is available for this paper.

• Publication year

  2015

• Venue

  CNS Spectrums

• Publication date

  2015-06-11

• Fields of study

  Medicine, Chemistry, Psychology

• Identifiers
  DOI 10.1017/S1092852915000358PMID 26062986
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data.

  2015cited by this paper
• Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): enhancing serotonin release by combining serotonin (5HT) transporter inhibition with actions at 5HT receptors (5HT1A, 5HT1B, 5HT1D, 5HT7 receptors)

  2015cited by this paper
• A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder

  2015cited by this paper
• A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults

  2014cited by this paper
• Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats.

  2013cited by this paper
• Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters--a rat microdialysis and electrophysiology study.

  2013cited by this paper
• Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction

  2013cited by this paper
• The last Diagnostic and Statistical Manual (DSM): replacing our symptom-based diagnoses with a brain circuit-based classification of mental illnesses

  2013cited by this paper
• A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder

  2012cited by this paper
• Pharmacological Effects of Lu AA21004: A Novel Multimodal Compound for the Treatment of Major Depressive Disorder

  2012cited by this paper
• The 5-Hydroxytryptamine4 Receptor Agonists Prucalopride and PRX-03140 Increase Acetylcholine and Histamine Levels in the Rat Prefrontal Cortex and the Power of Stimulated Hippocampal θ Oscillations

  2012cited by this paper
• Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.

  2011cited by this paper
• Research domain criteria (RDoC): toward a new classification framework for research on mental disorders.

  2010cited by this paper
• Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission.

  2007cited by this paper
• 5-HT Receptor Regulation of Neurotransmitter Release

  2007cited by this paper
• Rapid desensitization of somatodendritic 5‐HT1A receptors by chronic administration of the high‐efficacy 5‐HT1A agonist, F13714: a microdialysis study in the rat

  2006cited by this paper
• Involvement of 5-HT1A Receptors in Prefrontal Cortex in the Modulation of Dopaminergic Activity: Role in Atypical Antipsychotic Action

  2005cited by this paper
• Effect of a 5-HT(1A) receptor agonist, flesinoxan, on the extracellular noradrenaline level in the hippocampus and on the locomotor activity of rats.

  2000cited by this paper
• Role of 5‐HT1A autoreceptors in the mechanism of action of serotoninergic antidepressant drugs: recent findings from in vivo microdialysis studies

  1996cited by this paper
• Effect of Pindolol on the Function of Pre- and Postsynaptic 5-HT1A Receptors: In Vivo Microdialysis and Electrophysiological Studies in the Rat Brain

  1996cited by this paper
• A critical role for D1 receptors in the 5-HT1A-mediated facilitation of in vivo acetylcholine release in rat frontal cortex.

  1996cited by this paper
• Increase of noradrenaline release in the hypothalamus of freely moving rat by postsynaptic 5‐hydroxytryptamine1A receptor activation

  1995cited by this paper
• Hippocampal Serotonin 5‐HT1A Receptor Enhances Acetylcholine Release in Conscious Rats

  1994cited by this paper
• Acetylcholine release from rat hippocampal slices is modulated by 5-hydroxytryptamine.

  1989cited by this paper
• Electrophysiological responses of serotoninergic dorsal raphe neurons to 5‐HT1A and 5‐HT1B agonists

  1987cited by this paper
• Cholinergic terminals in rat hippocampus possess 5-HT1B receptors mediating inhibition of acetylcholine release.

  1986cited by this paper

• Revisiting the Role of Serotonin in Attention-Deficit Hyperactivity Disorder: New Insights from Preclinical and Clinical Studies

  2025cites this paper
• Vortioxetine alleviates motor, cognitive and emotional disorders in post-stroke rats by regulating the TLR-2/NF-κB pathway

  2025cites this paper
• Vortioxetine improved schizophrenia‐like behavioral deficits in a Poly I:C‐induced maternal immune activation model of schizophrenia in rats

  2024cites this paper
• Vortioxetine as an alternative treatment for somatic symptom disorder: case report

  2024cites this paper
• Effectiveness of Vortioxetine for the Treatment of Emotional Blunting in Patients with Major Depressive Disorder Experiencing Inadequate Response to SSRI/SNRI Monotherapy in Spain: Results from the COMPLETE Study

  2024cites this paper
• Association between NTRK2 Polymorphisms, Hippocampal Volumes and Treatment Resistance in Major Depressive Disorder

  2023cites this paper
• Pharmacological and Non-Pharmacological Treatments for Depression in Parkinson’s Disease: An Updated Review

  2023cites this paper
• Recent Developments in Pharmacotherapy of Depression: Bench to Bedside

  2023influential citation
• Role of vortioxetine in the treatment of neuropathic pain.

  2022cites this paper
• VORTIOXETINE TREATMENT DECREASES COCAINE-INDUCED LOCOMOTOR SENSITIZATION IN RATS.

  2022cites this paper
• Vortioxetine ameliorates motor and cognitive impairments in the rotenone-induced Parkinson's disease via targeting TLR-2 mediated neuroinflammation.

  2022cites this paper
• Role of vortioxetine in the treatment of neuropathic pain.

  2021cites this paper
• Vortioxetine Improved Depressive State In Parkinson’s Disease

  2021cites this paper
• Vortioxetine versus other antidepressants in the treatment of Burning Mouth Syndrome: an open-label randomized trial.

  2020cites this paper
• Vortioxetine as adjunctive therapy to risperidone for treatment of patients with chronic schizophrenia: A randomised, double-blind, placebo-controlled clinical trial

  2020cites this paper
• Effectiveness of Vortioxetine on Emotional Blunting in Patients with Major Depressive Disorder with inadequate response to SSRI/SNRI treatment.

  2020cites this paper
• Vortioxetine for Cognitive Enhancement in Major Depression: From Animal Models to Clinical Research

  2019cites this paper
• Vortioxetine for attention deficit hyperactivity disorder in adults: A randomized, double-blind, placebo-controlled, proof-of-concept study

  2019cites this paper
• Successful Vortioxetine Monotherapy for an Adolescent With Treatment-Resistant Obsessive-Compulsive Disorder.

  2019cites this paper
• Vortioxetine: A new alternative for the treatment of major depressive disorder

  2018cites this paper
• Successful Add-on Vortioxetine for an Adolescent With Attention-Deficit/Hyperactivity Disorder.

  2018cites this paper
• Opinion paper: poor response to treatment of depression in people in high occupational levels

  2018cites this paper
• Assessment and Management of Cognitive and Psychosocial Dysfunctions in Patients With Major Depressive Disorder: A Clinical Review

  2018cites this paper
• Current and Future Perspectives on the Major Depressive Disorder: Focus on the New Multimodal Antidepressant Vortioxetine.

  2017cites this paper
• Störungen der Neurobiochemie und Signaltransduktion als Grundlage psychischer Erkrankungen

  2017cites this paper
• Alteration of Monoaminergic Neuronal Firing by Acute Administration of Cariprazine: An In Vivo Electrophysiological Study

  2017cites this paper
• Vortioxetine: A new alternative for the treatment of major depressive disorder.

  2017cites this paper
• How to Control Weight Gain When Prescribing Antidepressants: Address Diet and Exercise First, Then Consider Switching Antidepressants or Prescribing an Adjunctive Agent

  2016cites this paper
• Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): modifying serotonin’s downstream effects on glutamate and GABA (gamma amino butyric acid) release

  2015cites this paper
• Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): blocking 5HT3 receptors enhances release of serotonin, norepinephrine, and acetylcholine

  2015cites this paper